NCT03160339View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

November 27, 2017

Study Completion Date

November 27, 2017

Conditions
Adenoviral Infection
Interventions
BIOLOGICAL

PXVX0047 Vaccine

PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.

BIOLOGICAL

Teva Ad4/Ad7 Vaccine

Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.

Trial Locations (2)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

05401

University of Vermont Medical Center, Burlington

Sponsors
All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

Emergent BioSolutions

INDUSTRY